Pipeline / 04 · Infrastructure

SA Trial Hospital

A fast-track clinical trial hospital platform in South Africa — accelerating first-in-human studies for therapeutics targeting high-burden African diseases.

THE TRIAL-TO-BURDEN MISMATCH Trials happen here. Disease happens there. WHERE TRIALS RUN 72% N. America + EU 22% Asia 6% Africa WHERE HIV DISEASE LIVES 5% N. America + EU 20% Asia 67% Africa Rough indicative figures — trial geography persistently lags disease geography.
Clinical trials for diseases with African epidemiological burden are still conducted predominantly in North America and Europe. The populations most affected are least represented in the trial data that informs treatment decisions.
Premise

The problem we are solving.

Most clinical trials for diseases with African epidemiological burden are still conducted primarily in North America and Europe. Trial infrastructure in the regions where HIV, TB, and cervical cancer are most prevalent remains limited — slowing translation and producing data that may not reflect the populations most affected.

South Africa, with established academic medicine, regulatory infrastructure, and direct access to the affected populations, is uniquely positioned to host first-in-human clinical work for therapeutics designed for African disease contexts. The SA Trial Hospital is the operational footprint of that thesis.

Approach

How we tackle it.

The SA Trial Hospital operates in collaboration with the University of KwaZulu-Natal and partner academic medical centers, providing GCP-compliant trial execution capacity for first-in-human studies. Programmatic focus is on therapies designed for the African disease burden — HIV functional cure, TB rapid diagnostics, HPV therapeutics, and pandemic-response platforms.

The Trial Hospital is the upstream operational complement to the Lesotho SMPZ: South Africa hosts academic-grade Phase I/II trials with established regulatory infrastructure, while the Lesotho SMPZ provides a sovereign regulatory sandbox for accelerated studies and longer-term GMP manufacturing scale-up. Together they form an integrated Southern African clinical development corridor.

CORRIDOR · SA TRIAL HOSPITAL × LESOTHO SMPZ Upstream and downstream, paired by design. UPSTREAM SA Trial Hospital Durban, South Africa → Phase I / II academic trials → U. KwaZulu-Natal anchor → SAHPRA regulatory infrastructure → Population-relevant enrollment validated candidates regulatory sandbox DOWNSTREAM Lesotho SMPZ Eastern highlands, Lesotho → Phase II / III at scale → Sovereign regulatory sandbox → GMP manufacturing + CryoVault → Wellness + recovery infrastructure
SA Trial Hospital and Lesotho SMPZ operate as a paired corridor — academic-grade Phase I/II validation at the KwaZulu-Natal anchor, followed by Phase II/III regulatory-sandbox deployment at the Lesotho SMPZ.
Capabilities

What makes this real.

01
Population-relevant trial sites
Direct access to patient cohorts most affected by HIV, TB, cervical cancer, and other African disease-burden conditions — closing the data-relevance gap.
02
Academic-medical anchor
Operating with the University of KwaZulu-Natal — established regulatory infrastructure, GCP compliance, and established ethics-board pathways.
03
Cross-corridor with Lesotho SMPZ
Phase I/II trials in South Africa flow into Lesotho SMPZ regulatory acceleration and GMP scale-up — integrated Southern African clinical development corridor.
04
Multi-program throughput
Trial sites support HIV, TB, HPV, and pandemic-preparedness programs simultaneously — infrastructure cost amortizes across MACRO HRD's full venture portfolio.
Where It Connects

Part of an integrated platform.

04 · Infrastructure
Lesotho SMPZ
A sovereign Special Medical Practice Zone in Lesotho's eastern highlands — concentrating regulatory authority, GMP infrastructure, AI platforms, and CryoVault biobanking in a single jurisdiction.
02 · Infectious Disease
HIV Functional Cure Program
An integrated therapeutic approach combining tri-specific antibodies, CAR-like NK effectors, AH-D peptide activation, and GEDM-3DQ-guided coordination.
02 · Infectious Disease
TB Rapid Diagnostic Platform
Next-generation tuberculosis diagnostic technology engineered for public health deployment in high-burden regions.
04 · Infrastructure
Ambient Cell Logistics
Room-temperature cell logistics — a bioinspired sporulation strategy that ends cold-chain dependency for cellular therapies.
⸻ Continue the platform

“Trials in the populations the therapy is for. That is not a luxury. It is the work.”

See all ventures → Engage with MACRO HRD